Form 4: Entrada Therapeutics CFO Executes Stock Transactions Under 10b5-1 Plan

Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, executed multiple stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Summary

• Kory James Wentworth, the Chief Financial Officer of Entrada Therapeutics, executed transactions involving the company's common stock and stock options.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2024.
• On November 29, 2024, Mr. Wentworth exercised options to acquire 1,000 shares at $2.10 per share and sold 1,000 shares at a weighted average price of $19.9703.
• On December 2, 2024, he exercised options to acquire 5,000 shares at $2.10 per share and sold 5,000 shares at a weighted average price of $19.9956.
• Following these transactions, Mr. Wentworth beneficially owns 73,849 shares of common stock and 31,157 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan. There is no indication of positive or negative sentiment, it is a neutral disclosure.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.
• The CFO exercised stock options at a price of $2.10 and sold the shares at a significantly higher price, indicating a potential profit.

Risks

• The sale of shares by a high-ranking executive could be perceived negatively by the market, potentially leading to a decrease in the stock price.
• The transactions are part of a pre-arranged plan, but the market may still react to the news of insider selling.

Industry Context

This type of filing is common for executives at publicly traded companies and is a routine disclosure of insider trading activity. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Entrada Therapeutics.
• Similar filings are regularly made by executives at companies like BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals, reflecting routine stock transactions under pre-arranged plans.
• The reported prices for the stock sales are within the typical range for market transactions, and the option exercise price is consistent with standard option grants.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as the sale of shares by an executive could be perceived negatively.
• The transactions are part of a pre-arranged plan, which should mitigate any significant negative impact.

Key Dates

Keywords

Entrada Therapeutics, Kory James Wentworth, CFO, stock options, 10b5-1 trading plan, insider trading, stock sale, SEC Form 4